PIK3CA and colorectal carcinoma: In vitro data from our study gave rationale for abemaciclib and BYL719 combination therapy, and in vivo data with a PIK3CA mutated CRC mouse xenograft model confirmed the efficacy of abemaciclib and BYL719 combination therapy.